Tag: management

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

TORONTO, June 25, 2026 /CNW/ - Power Metallic Mines Inc. (the "Company" or "Power Metallic") (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1) is pleased to announce...

Thunes awarded Platinum for Best Cross-Border Platform and Gold for Best B2B Payments, recognising its position as the engine connecting disparate local and global...

LONDON, June 25, 2026 /PRNewswire/ -- BPC has been recognised with three prestigious titles at the Global Brand Awards 2026, organised by Global Brands Magazine...

DEMIRE baut ESG-Datenbasis auf nahezu gesamtes Portfolio aus und treibt Dekarbonisierung weiter voran

DEMIRE is expanding its ESG database to cover almost its entire portfolio and is continuing to drive forward decarbonization

BEIJING, June 25, 2026 /PRNewswire/ -- Chinese President Xi Jinping has called for solid measures to advance the modernization of agriculture and rural areas,...

SAN FRANCISCO, June 24, 2026 /PRNewswire/ -- The global digital health market is expected to witness significant expansion over the coming years, with the...

CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel...

Free Vouchers Worth Up to HK$1,000, 5x Weekend Points, and Flash Deals Delivering Up to 100% Cashback on Dining, Shopping & FunHONG KONG, June 25,...

NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

RUTHERFORD, N.J., June 24, 2026 /PRNewswire/ -- Kreyco Inc., a provider of educational services to New York City public schools between 2023 and 2025,...

TORONTO, June 24, 2026 /CNW/ - Jamieson Wellness Inc. ("Jamieson" or the "Company") (TSX: JWEL) acknowledges a recent media report regarding a potential sale...